Verzenio vs Imbruvica
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Verzenio | US Imbruvica | |
|---|---|---|
| Generic name | abemaciclib | ibrutinib |
| Drug class | CDK4/6 Inhibitor | BTK Inhibitor |
| Treats | HR+/HER2- breast cancer | Chronic lymphocytic leukemia and other blood cancers |
| Category | Oncology | Oncology |
| Manufacturer | Eli Lilly | AbbVie/Janssen |
| Year approved | 2017 | 2013 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Diarrhea, Low blood counts, Fatigue, Blood clots | Bleeding and bruising, Irregular heartbeat (atrial fibrillation), High blood pressure, Infections |
Imbruvica
Frequently asked questions
Is Verzenio or Imbruvica better?
Neither is universally "better." Verzenio (abemaciclib) and Imbruvica (ibrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Verzenio and Imbruvica?
Verzenio is a CDK4/6 Inhibitor made by Eli Lilly, while Imbruvica is a BTK Inhibitor made by AbbVie/Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Verzenio has the larger estimated TV advertising budget of the two.